With Takhzyro Approval, Shire Could Reclaim HAE Prophylaxis Market From CSL Behring

Offering better efficacy than Shire’s existing HAE therapies and dosing convenience compared to CSL Behring’s prophylactic Haegarda, the specialty pharma may take back market share lost to its competitor and consolidate its leadership in the space.

Red Approved Stamp with Wooden handle Rubber Stamper Isolated on White Background.

US FDA approval for Shire PLC’s Takhzyro as a subcutaneous prophylactic for attacks of hereditary angioedema should position the company to begin winning back market share lost to CSL Behring’s prophylactic agent Haegarda. Analysts predict rapidly ramping sales for Takhzyro, reaching blockbuster totals in just a few years.

Unlike Haegarda, which inhibits HAE patients’ C1 esterase levels, Takhzyro (lanadelumab-flyo) is a kallikrein-inhibiting monoclonal antibody. It is the first...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip